ABVC BioPharma, Inc. Accumulated Other Comprehensive Income
ABVC BioPharma, Inc. (ECOC) had Accumulated Other Comprehensive Income of $498.19 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $498.19K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $499.65K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $487.60K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $487.05K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $498.19K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $499.65K 10-Q · filed 2026-05-18 |
| 2025-12-31 | $487.60K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $487.05K 10-Q/A · filed 2026-03-03 |
| 2025-06-30 | $483.81K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $444.17K 10-Q · filed 2025-04-30 |
| 2024-12-31 | $445.67K 10-Q/A · filed 2026-03-03 |
| 2024-09-30 | $461.28K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $435.89K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $233.32K 10-Q · filed 2024-05-17 |
| 2023-12-31 | $516.39K 10-K · filed 2025-04-15 |
| 2022-12-31 | $517.13K 10-K · filed 2024-03-13 |
| 2022-06-30 | $303.10K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $426.32K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $539.66K 10-Q · filed 2022-08-15 |
| 2021-09-30 | $981.72K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $965.58K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $601.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $564.86K 10-K · filed 2022-03-31 |